2017 AHA/ACC/HRS 室性心律失常与心源性猝死预防指南的系统综述
该系统综述针对2017年AHA/ACC/HRS室性心律失常指南的两个问题进行分析:无症状Brugada综合征患者电生理检查诱发室性心律失常是否预示高风险,以及ICD在老年和合并症患者中的临床获益。结果显示诱发性室性心律失常的OR为2.3(95%CI 0.63-8.66;P=0.2),无统计学意义;ICD植入与改善生存相关(HR 0.75;95%CI 0.67-0.83;P<0.001),在合并症患者中亦降低全因死亡率(HR 0.72;95%CI 0.65-0.79;P<0.0001)。
要点
- 无症状Brugada综合征患者电生理检查诱发室性心律失常未显著增加主要心律失常事件风险。
- ICD植入与老年及合并症患者生存改善相关,支持在符合条件者中应用。
- 肾功能不全患者ICD植入亦与全因死亡率降低相关(HR 0.71;95%CI 0.60-0.85)。
核心结论
- 无症状Brugada综合征患者电生理检查诱发室性心律失常与主要心律失常事件风险无显著关联。
- ICD植入在老年和合并症患者中与生存改善相关。
研究设计与样本
- 系统综述,纳入6项研究共1138例无症状Brugada综合征患者。
主要发现
- 无症状Brugada综合征患者中390例(34.3%)电生理检查可诱发室性心律失常。
- 主要分析使用5项研究,诱发室性心律失常 vs 未诱发的主要心律失常事件OR为2.3(95%CI 0.63-8.66;P=0.2)。
- ICD植入与改善生存相关(总体HR 0.75;95%CI 0.67-0.83;P<0.001)。
- 合并症患者ICD使用与全因死亡率降低相关(随机效应模型HR 0.72;95%CI 0.65-0.79;P<0.0001)。
- 肾功能不全患者ICD植入与全因死亡率降低相关(HR 0.71;95%CI 0.60-0.85;P<0.001)。
临床怎么用
- 对于无症状Brugada综合征患者,电生理检查诱发室性心律失常不应单独作为风险分层依据。
- 老年及合并症患者若符合ICD植入指征,植入ICD可能带来生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although large randomized clinical trials have found that primary prevention use of an implantable cardioverter-defibrillator (ICD) improves survival in patients with cardiomyopathy and heart failure symptoms, patients who receive ICDs in practice are often older and have more comorbidities than patients who were enrolled in the clinical trials. In addition, there is a debate among clinicians on the usefulness of electrophysiological study for risk stratification of asymptomatic patients with Brugada syndrome. AIM: Our analysis has 2 objectives. First, to evaluate whether ventricular arrhythmias (VAs) induced with programmed electrostimulation in asymptomatic patients with Brugada syndrome identify a higher risk group that may require additional testing or therapies. Second, to evaluate whether implantation of an ICD is associated with a clinical benefit in older patients and patients with comorbidities who would otherwise benefit on the basis of left ventricular ejection fraction and heart failure symptoms. METHODS: Traditional statistical approaches were used to address 1) whether programmed ventricular stimulation identifies a higher-risk group in asymptomatic patients with Brugada syndrome and 2) whether ICD implantation for primary prevention is associated with improved outcomes in older patients (>75 years of age) and patients with significant comorbidities who would otherwise meet criteria for ICD implantation on the basis of symptoms or left ventricular function. RESULTS: Evidence from 6 studies of 1138 asymptomatic patients were identified. Brugada syndrome with inducible VA on electrophysiological study was identified in 390 (34.3%) patients. To minimize patient overlap, the primary analysis used 5 of the 6 studies and found an odds ratio of 2.3 (95% CI: 0.63-8.66; P=0.2) for major arrhythmic events (sustained VAs, sudden cardiac death, or appropriate ICD therapy) in asymptomatic patients with Brugada syndrome and inducible VA on electrophysiological study versus those without inducible VA. Ten studies were reviewed that evaluated ICD use in older patients and 4 studies that evaluated unique patient populations were identified. In our analysis, ICD implantation was associated with improved survival (overall hazard ratio: 0.75; 95% confidence interval: 0.67-0.83; P<0.001). Ten studies were identified that evaluated ICD use in patients with various comorbidities including renal disease, chronic obstructive pulmonary disease, atrial fibrillation, heart disease, and others. A random effects model demonstrated that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.72; 95% confidence interval: 0.65-0.79; P<0.0001), and a second "minimal overlap" analysis also found that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.71; 95% confidence interval: 0.61-0.82; P<0.0001). In 5 studies that included data on renal dysfunction, ICD implantation was associated with reduced all-cause mortality (overall hazard ratio: 0.71; 95% confidence interval: 0.60-0.85; P<0.001).
引用
- Kusumoto FM, Bailey KR, Chaouki AS, et al. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018. PMID: 29084732. doi:10.1161/CIR.0000000000000550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。